NCT06533007Enrolling by invitation
PDE3B in Metabolic Regulation
The Role of Phosphodiesterase 3B in the Regulation of Human Adipose Tissue Biology and Systemic Glucose and Lipid Homeostasis
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
Phosphodiesterase 3B (PDE3B), an enzyme responsible for the degradation of cyclic AMP and GMP (two important second messengers used for intracellular signal transduction), has been associated with cardiometabolic outcomes. Results from animal studies indicate that abolishing PDE3B function may be associated with unfavourable metabolic profile; however, preliminary human studies suggest that heterozygous loss of function (LoF) variants in the PDE3B gene have been associated with cardiometabolic improvements. Therefore, the effect of PDE3B on human adipose tissue metabolic pathways remains poorly understood. Accordingly, the investigators propose to conduct a recall-by-genotype, case-control study in a group of people with LoF variants in the PDE3B gene and a matched group without the variant (wild type, WT) to determine differences on key metabolic features: 1) adipose tissue biology (i.e., mitochondrial function, adipocyte morphology, gene expression and in vivo lipolysis in the basal and/or the insulin-stimulated state); 2) systemic lipid and glucose metabolism using the hyperinsulinemic-euglycemic clamp procedure. The proposed investigations will elucidate the role of PDE3B on adipose tissue and systemic glucose and lipid metabolism in humans and whether modulating PDE3B activity constitutes a target for the prevention and treatment of cardiometabolic disease.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 17 Jul 2024
- Start date
- 1 Sept 2025
- Primary completion date
- Sept 2028
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Diseases
- Type 2 diabetes
- NCT number
- NCT06533007
What you commit to
- Study type: Observational
- Planned participants: 40
- From 1 Sept 2025 to the primary completion date, Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- gastrointestinal or bariatric surgery (except cholecystectomy and appendectomy)
- use of medications that affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued
- illegal drug use
Other illness
- type 2 diabetes or other major organ dysfunction
- cancer in last 5 years
- conditions that render subject unable to complete all testing procedures (including individuals with known allergies or contraindications to the medications used in this study)
Other
- unstable weight (\>5% change the last 2 months)
- smoking
- pregnant or lactating
- unable to grant voluntary informed consent or comply with the study instructions
Who the study is looking for
- willing and able to give informed consent for participation in the study
- aged 21-75 years
- men and women
Age in the registry: 21 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cambridge university hospital Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.